- Home
- DOCS vs SNN Comparison
DOCS vs SNN Comparison
Compare DOCS & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | SNN |
|---|---|---|
| Founded | 2010 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 14.3B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOCS | SNN |
|---|---|---|
| Price | $24.83 | $32.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 2 |
| Target Price | ★ $50.86 | $36.25 |
| AVG Volume (30 Days) | ★ 2.4M | 781.6K |
| Earning Date | 02-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.28% |
| EPS Growth | ★ 54.17 | N/A |
| EPS | ★ 0.88 | N/A |
| Revenue | ★ $570,399,000.00 | N/A |
| Revenue This Year | $15.05 | $7.19 |
| Revenue Next Year | $8.99 | $5.36 |
| P/E Ratio | ★ $28.10 | $64.97 |
| Revenue Growth | ★ 19.98 | N/A |
| 52 Week Low | $23.53 | $23.91 |
| 52 Week High | $76.51 | $38.79 |
Technical Indicators
Market Signals| Indicator | DOCS | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 34.33 | 35.24 |
| Support Level | $23.59 | $32.15 |
| Resistance Level | $27.09 | $33.89 |
| Average True Range (ATR) | 1.04 | 0.69 |
| MACD | 0.47 | -0.31 |
| Stochastic Oscillator | 25.85 | 6.61 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.